selected publications
-
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
Cancer.
2020
Academic Article
GET IT
Times cited: 4 -
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020
Academic Article
GET IT
Times cited: 26 -
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
JAMA oncology.
2020
Academic Article
GET IT
Times cited: 92 -
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients.
European journal of cancer (Oxford, England : 1990).
2020
Review
GET IT
Times cited: 185 -
Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis.
Cancer.
2019
Academic Article
GET IT
Times cited: 24 -
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Cancer.
2019
Academic Article
GET IT
Times cited: 18 -
Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy.
2019
GET IT
Times cited: 46 -
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
Investigational new drugs.
2018
Academic Article
GET IT
Times cited: 26 -
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
British journal of cancer.
2018
Academic Article
GET IT
Times cited: 2 -
Reply to E. Younger et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Letter
GET IT
Times cited: 1 -
Locally Aggressive Connective Tissue Tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017
Review
GET IT
Times cited: 40 -
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Ophthalmology.
2017
Academic Article
GET IT
Times cited: 80 -
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 1922 -
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 14 -
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Investigational new drugs.
2017
Academic Article
GET IT
Times cited: 10 -
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
Investigational new drugs.
2017
Academic Article
GET IT
Times cited: 12 -
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 92 -
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 114 -
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
JAMA oncology.
2016
Academic Article
GET IT
Times cited: 201 -
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.
Sarcoma.
2016
Academic Article
GET IT
Times cited: 693 -
Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Genes, chromosomes & cancer.
2016
Academic Article
GET IT
Times cited: 46 -
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Cancer.
2016
Academic Article
GET IT
Times cited: 8 -
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
2016
GET IT
Times cited: 225 -
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
The oncologist.
2015
Academic Article
GET IT
Times cited: 23 -
Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?".
Cancer.
2015
Editorial Article
GET IT
Times cited: 14 -
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Academic Article
GET IT
Times cited: 15 -
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.
European journal of cancer (Oxford, England : 1990).
2015
Academic Article
GET IT
Times cited: 69 -
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 11 -
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.
Oncotarget.
2015
Academic Article
GET IT
Times cited: 12 -
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma.
Oncology.
2015
Academic Article
GET IT
Times cited: 34 -
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.
Sarcoma.
2015
Academic Article
GET IT
Times cited: 63 -
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
Human pathology.
2014
Academic Article
GET IT
Times cited: 212 -
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2014
Academic Article
GET IT
Times cited: 47 -
Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2014
Academic Article
GET IT
Times cited: 2 -
Reply to M. Voskoboynik et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Letter
GET IT
Times cited: 1 -
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 31 -
Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells.
Cell death & disease.
2013
Academic Article
GET IT
Times cited: 182 -
High-risk features in radiation-associated breast angiosarcomas.
British journal of cancer.
2013
Academic Article
GET IT
Times cited: 48 -
Multidisciplinary management of recurrent chordomas.
Current treatment options in oncology.
2013
Academic Article
GET IT
Times cited: 20 -
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013
Academic Article
GET IT
Times cited: 330 -
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
Cancer discovery.
2013
Academic Article
GET IT
Times cited: 572 -
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012
Academic Article
GET IT
Times cited: 19 -
Moving forward one Notch at a time.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2012
Editorial Article
GET IT
Times cited: 15 -
Inclusion of patients with brain metastases in phase I trials: an unmet need.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Comment
GET IT
Times cited: 12 -
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 198 -
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Cancer chemotherapy and pharmacology.
2010
Review
GET IT
Times cited: 68 -
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
The Lancet. Oncology.
2008
Review
GET IT
Times cited: 111 -
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
British journal of haematology.
2007
Academic Article
GET IT
Times cited: 73